PAncreatic Disease Cohort of TOuLouse
ConditionPancreatic Diseases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Toulouse
About this trial
This study is a prospective cohort dedicated to pancreatic diseases excluding cancer. The aim is to develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies. During this study the investigators collect data and biological samples to support research project.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with inflammatory or cystic exocrine pancreatic pathology
Patient able to read and understand the information leaflet
Patients who have agreed to participate in the study and have signed the free and informed consent
Patients affiliated to a social security system (including AME)
Disqualifiers
Patient with pancreatic cancer pathology
Patients with active cancer, whatever the origin
Pregnant or breastfeeding patients
Patients under legal protection, guardianship or trusteeship
Trial population
Patients with pancreatic disease
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Diagnostic tools
To develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies
Time frame
3 years after the first inclusionSecondary outcomes
1
New targets
To identify new screening targets
Time frame
3 years after the first inclusion2
Improvement of management
To improve the management of cystic lesions or Chronic pancreatitis on the decision of therapeutic management
Time frame
3 years after the first inclusion3
Microbiota
Study of the microbiota of pancreatic diseases
Time frame
3 years after the first inclusion4
Clinical data access
To make available to the scientific community quality material with associated clinical data also of quality
Time frame
3 years after the first inclusionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov